TICKERNERD
Menu
ROIVROIVHealthcare · Biotechnology

ROIV Stock Forecast: Roivant Sciences Ltd. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$34
−1.55% on the day

The 13 Wall Street analysts covering Roivant Sciences Ltd. hold a median 12-month price target of $47 — +35.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$25.1B
Ticker Nerd rank
35 / 100
Median analyst target
$47
Analysts covering
13
Revenue$1.4M−33.5% y/y
Operating income−$366.4M
Net income−$290.6M
Free cash flow−$270.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.6%
1M
−17.5%
YTD
+57.6%
1Y
+113.4%
From 52W high
−18.2%
From 52W low
+113.4%
$16
$42
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ROIV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Roivant Sciences Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
93
Momentum
90
Growth
55
Issuance
54
Value
47
Revisions
42
Quality
34
Accruals
16
Size
9

Volatility (93): The share price has been relatively steady.

Accruals (16): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (9): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ROIV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ROIV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26ROIVHigh $55Median $47Low $41

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
12 Buy1 Hold0 Sell
Low $41Median $47High $55

The green dot is the last close — the median target sits +35.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
17 Sept 2026StifelInitiatesBuy$51
9 Sept 2026GuggenheimMaintainsBuy—
9 Sept 2026GuggenheimMaintainsBuy$42 → $46
9 Sept 2026TD CowenMaintainsBuy—
9 Sept 2026TD CowenMaintainsBuy$50 → $55
8 Sept 2026HC Wainwright & Co.MaintainsBuy$41 → $47
8 Sept 2026HC Wainwright & Co.MaintainsBuy—
8 Sept 2026JefferiesMaintainsBuy—
8 Sept 2026JefferiesMaintainsBuy$42 → $52
28 Aug 2026HC Wainwright & Co.ReiteratesBuy—
28 Aug 2026HC Wainwright & Co.ReiteratesBuy$41
10 Aug 2026CitigroupMaintainsBuy—
10 Aug 2026CitigroupMaintainsBuy$42 → $46
7 Aug 2026GuggenheimMaintainsBuy$36 → $42
7 Aug 2026GuggenheimMaintainsBuy—
7 Aug 2026HC Wainwright & Co.MaintainsBuy$34 → $41
7 Aug 2026HC Wainwright & Co.MaintainsBuy—
26 May 2026GuggenheimMaintainsBuy—
26 May 2026GuggenheimMaintainsBuy$30 → $36
21 May 2026CitigroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ROIV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ROIV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Roivant Sciences Ltd. returned +113.4% against +16.2% for the S&P 500, dividends included.

ROIV vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26ROIVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ROIV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Roivant Sciences Ltd. (ROIV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.9×

Cheaper than 70% of US stocks

Price / sales
3332.5×

Cheaper than 1% of US stocks

Price / book
5.9×

Cheaper than 17% of US stocks

EV / EBITDA
−16.2×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
−33.5%

Higher than 8% of US stocks

Earnings growth (YoY)
−33.5%

Higher than 15% of US stocks

Gross margin
80.3%

Higher than 91% of US stocks

Operating margin
−25408.1%

Higher than 1% of US stocks

Net margin
84.4%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−8.5%

Higher than 37% of US stocks

Return on assets
−16.5%

Higher than 22% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Roivant Sciences Ltd. (ROIV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Roivant Sciences Ltd. has a market value of $25.1B and an enterprise value of $22.1B.

  • Revenue in the twelve months to 30 June 2026: $7.5M. The latest quarter shrank 33.5% year on year.

  • Net income over the same four quarters: −$414.6M, a −5504.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.53.

  • Free cash flow in the twelve months to 30 June 2026: −$821.1M.

  • Roivant Sciences Ltd. spent $317.9M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 722.7M.

  • Trailing P/E: 1.9×; forward P/E: −20.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Roivant Sciences Ltd. employs 721 people — $10K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

ROIV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ROIVRoivant Sciences Ltd.$25.1B
35
INCYIncyte Corp.$22.5B
89
INSMInsmed, Inc.$21.9B
81
ALNYAlnylam Pharmaceuticals, Inc.$29.7B
51
RPRXRoyalty Pharma plc$32.4B
87
EXELExelixis, Inc.$15.3B
99
RVMDRevolution Medicines, Inc.$39.3B
45

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Roivant Sciences Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ROIV news & analysis

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months

MarketBeat · 28 Sept 2026neutral

Roivant Sciences CEO Matthew Gline outlined the company's priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant's IMVT-1402, and expansion of its pulmonary hypertension program.

Why it matters — A ROIV watcher would care because the company's stated priorities signal near-term catalysts, including a product launch and key pipeline readouts.

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

GlobeNewsWire · 23 Sept 2026negative

Immunovant announced topline results from its proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus. The study did not achieve statistical significance on the primary endpoint, and although positive trends and a favorable safety profile were observed, it did not meet Immunovant's internal bar to continue development in CLE. All other clinical development timelines remain on track.

Why it matters — Immunovant is a Roivant affiliate, so a discontinued development program in CLE represents a setback for its pipeline, even though other timelines remain unaffected.

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

GlobeNewsWire · 23 Sept 2026negative

Roivant announced topline results from Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE). The study did not achieve statistical significance on the primary endpoint at Week 12 and did not meet Immunovant's internal bar to continue development of the drug in CLE, though positive trends and a favorable safety profile were observed.

Why it matters — The failure of IMVT-1402 to meet the primary endpoint in CLE ends that development path for a Roivant pipeline candidate, while other clinical timelines remain on track.

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha · 22 Sept 2026neutral

Roivant Sciences Ltd. (ROIV) presented at the Bank of America Global Healthcare Conference 2026, with a transcript of the presentation published by Seeking Alpha.

Why it matters — A ROIV watcher would care because the conference presentation transcript offers an official record of what the company's leadership discussed with investors at a major industry event.

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

Seeking Alpha · 13 Sept 2026positive

A Seeking Alpha analysis notes that LISRAYA's recent approval gives Roivant Sciences a commercial foundation, while brepocitinib could potentially expand into a broader immunology franchise with additional indications. The piece also highlights ROIV's pulmonary asset mosliciguat as promising, while noting that its subsequent Phase 3 results remain to be seen.

Why it matters — A ROIV watcher would care because the piece outlines the company's diversified pipeline across commercial, immunology, and pulmonary franchises that could underpin future growth.

FAQ

Frequently asked questions about ROIV stock

What is the ROIV stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Roivant Sciences Ltd. have a median 12-month price target of $47, with estimates ranging from $41 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ROIV stock a buy right now?

Of the 13 analysts covering Roivant Sciences Ltd., 12 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Roivant Sciences Ltd. 35 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ROIV?

As at 8 Oct 2026, Roivant Sciences Ltd. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).

Will ROIV stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +35.9% from the last close, and Ticker Nerd's factor model ranks Roivant Sciences Ltd. 35 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ROIV stock forecast for 2030?

No analyst covering Roivant Sciences Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ROIV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $41 to $55 over the next 12 months.

How has ROIV stock performed over the past year?

Roivant Sciences Ltd. returned +113.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Roivant Sciences Ltd. do?

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies through a portfolio of specialized subsidiary companies.

What is the latest news on ROIV?

The most recent item we track (MarketBeat, 28 Sept 2026): "Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months". Roivant Sciences CEO Matthew Gline outlined the company's priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant's IMVT-1402, and expansion of its pulmonary hypertension program.

Company

About Roivant Sciences Ltd.

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies through a portfolio of specialized subsidiary companies. Roivant Sciences Ltd. operates across immunology, dermatology, and other high-unmet-need therapeutic areas, with current work spanning commercial products and clinical-stage candidates. Its business model emphasizes creating focused operating companies to advance individual drug programs, support partnering activities, and incubate complementary health technology initiatives. The company’s current product and pipeline portfolio includes therapies for autoimmune and inflammatory diseases, as well as treatments being studied in areas such as dermatologic conditions, uveitis, pulmonary hypertension, and rare diseases. Roivant Sciences Ltd. plays a distinctive role in the healthcare market by combining drug development expertise with an asset-centric structure designed to move promising medicines toward commercialization.

CEO Mr. Matthew Gline · 721 employees · United Kingdom · https://roivant.com